Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

Study of SilverHawk/TurboHawk in Lower Extremity Vessels (DEFINITIVE LE)
Determination of Effectiveness of SilverHawk Peripheral Plaque Excision (SilverHawk Device) for the Treatment of Infrainguinal Vessels/Lower Extremities
Status: Archived
Alice Heart Center
mi
from
Alice, TX
Study of SilverHawk/TurboHawk in Lower Extremity Vessels (DEFINITIVE LE)
Determination of Effectiveness of SilverHawk Peripheral Plaque Excision (SilverHawk Device) for the Treatment of Infrainguinal Vessels/Lower Extremities
Status: Archived
Updated: 1/1/1970
Alice Heart Center
mi
from
Alice, TX
Factor XI Levels in Acute Ischemic Stroke
Factor XI Levels in Acute Ischemic Stroke
Status: Archived
University Of Utah Hospital
mi
from
Salt Lake City, UT
Factor XI Levels in Acute Ischemic Stroke
Factor XI Levels in Acute Ischemic Stroke
Status: Archived
Updated: 1/1/1970
University Of Utah Hospital
mi
from
Salt Lake City, UT
Adenosine Dual Source Computed Tomography (CT) Versus Adenosine Single Photon Emission Computed Tomography (SPECT)
Coronary Anatomy and Physiology Using Multidetector Dual Source Computed Tomography With Adenosine Enhancement: Comparative Study With SPECT Imaging: Pilot Studies I/II
Status: Archived
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Adenosine Dual Source Computed Tomography (CT) Versus Adenosine Single Photon Emission Computed Tomography (SPECT)
Coronary Anatomy and Physiology Using Multidetector Dual Source Computed Tomography With Adenosine Enhancement: Comparative Study With SPECT Imaging: Pilot Studies I/II
Status: Archived
Updated: 1/1/1970
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Research Center of Southern California
mi
from
Oceanside, CA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Research Center of Southern California
mi
from
Oceanside, CA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Associated Neurologists, P.C.
mi
from
Danbury, CT
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Associated Neurologists, P.C.
mi
from
Danbury, CT
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Bradenton Research Center
mi
from
Bradenton, FL
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Bradenton Research Center
mi
from
Bradenton, FL
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Halifax Health Medical Center
mi
from
Daytona Beach, FL
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Halifax Health Medical Center
mi
from
Daytona Beach, FL
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Neuroscience Research Institute/Dekalb Neurology
mi
from
Lawrenceville, GA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Neuroscience Research Institute/Dekalb Neurology
mi
from
Lawrenceville, GA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Memorial Health University Medical Center
mi
from
Savannah, GA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Memorial Health University Medical Center
mi
from
Savannah, GA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
The University of Kentucky The Methodist Hospital
mi
from
Lexington, KY
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
The University of Kentucky The Methodist Hospital
mi
from
Lexington, KY
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
University of Louisville Hospital
mi
from
Louisville, KY
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
University of Louisville Hospital
mi
from
Louisville, KY
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
JFK Hospital
mi
from
Atlantis, FL
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
JFK Hospital
mi
from
Atlantis, FL
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Capital Health
mi
from
Trenton, NJ
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Capital Health
mi
from
Trenton, NJ
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
University of New Mexico
mi
from
Albuquerque, NM
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
University of New Mexico
mi
from
Albuquerque, NM
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Mission Hospital, Inc
mi
from
Asheville, NC
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Mission Hospital, Inc
mi
from
Asheville, NC
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Presbitarian Hospital
mi
from
Charlotte, NC
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Presbitarian Hospital
mi
from
Charlotte, NC
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Metro Health Medical Center
mi
from
Cleveland, OH
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Metro Health Medical Center
mi
from
Cleveland, OH
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
St. Elizabeths Medical Center
mi
from
Boston, MA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
St. Elizabeths Medical Center
mi
from
Boston, MA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Legacy Meridian Park Medical Center
mi
from
Tualatin, OR
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Legacy Meridian Park Medical Center
mi
from
Tualatin, OR
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Lehigh Valley Hospital Mental Health Clinic
mi
from
Allentown, PA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Lehigh Valley Hospital Mental Health Clinic
mi
from
Allentown, PA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Thomas Jefferson Hospital
mi
from
Philadelphia, PA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Thomas Jefferson Hospital
mi
from
Philadelphia, PA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Vanderiblt University Medical Center
mi
from
Nashville, TN
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Vanderiblt University Medical Center
mi
from
Nashville, TN
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Houston Methodist Hospital
mi
from
Houston, TX
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Houston Methodist Hospital
mi
from
Houston, TX
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Carilion Clinic
mi
from
Roanoke, VA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Carilion Clinic
mi
from
Roanoke, VA
Contribution of Hepatic and Intestinal Lipoproteins to Human Atherosclerosis
Contribution of Hepatic and Intestinal Lipoproteins to Human Atherosclerosis
Status: Archived
Piedmont Heart Institute
mi
from
Atlanta, GA
Contribution of Hepatic and Intestinal Lipoproteins to Human Atherosclerosis
Contribution of Hepatic and Intestinal Lipoproteins to Human Atherosclerosis
Status: Archived
Updated: 1/1/1970
Piedmont Heart Institute
mi
from
Atlanta, GA
The Influence of Daily Intake of Whole Grain Barley or Oats on Biomarkers of Cardiovascular Disease
Status: Archived
USDA Beltsville Human Nutrition Research Center
mi
from
Beltsville, MD
The Influence of Daily Intake of Whole Grain Barley or Oats on Biomarkers of Cardiovascular Disease
Status: Archived
Updated: 1/1/1970
USDA Beltsville Human Nutrition Research Center
mi
from
Beltsville, MD
Use of AEEG as Predictor of Long-term Motor Outcome in Neonates With Congenital Heart Disease
Use of AEEG as Predictor of Long-term Motor Outcome in Neonates With Congenital Heart Disease
Status: Archived
Mount Sinai Hospital
mi
from
New York, NY
Use of AEEG as Predictor of Long-term Motor Outcome in Neonates With Congenital Heart Disease
Use of AEEG as Predictor of Long-term Motor Outcome in Neonates With Congenital Heart Disease
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
mi
from
New York, NY
Lipid Rich Necrotic Core Lesion Detected by Cardiac Magnetic Resonance Imaging (CMR)
High Amount of Lipid Rich Necrotic Core Lesion Identified by Pre-interventional Intravascular Ultrasound (IVUS) is Associated With High Rate of Delayed Hyper-enhancement as Detected by Contrast-enhanced Cardiac Magnetic Resonance Imaging
Status: Archived
Piedmont Heart Institute
mi
from
Atlanta, GA
Lipid Rich Necrotic Core Lesion Detected by Cardiac Magnetic Resonance Imaging (CMR)
High Amount of Lipid Rich Necrotic Core Lesion Identified by Pre-interventional Intravascular Ultrasound (IVUS) is Associated With High Rate of Delayed Hyper-enhancement as Detected by Contrast-enhanced Cardiac Magnetic Resonance Imaging
Status: Archived
Updated: 1/1/1970
Piedmont Heart Institute
mi
from
Atlanta, GA
Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)
CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)
Status: Archived
St. Elizabeths Medical Center
mi
from
Boston, MA
Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)
CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)
Status: Archived
Updated: 1/1/1970
St. Elizabeths Medical Center
mi
from
Boston, MA
Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)
CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)
CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)
CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)
Status: Archived
St Joseph's Comprehensive Research Institute
mi
from
Tampa, FL
Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)
CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)
Status: Archived
Updated: 1/1/1970
St Joseph's Comprehensive Research Institute
mi
from
Tampa, FL
Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)
CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)
Status: Archived
VCU Medical Center
mi
from
Richmond, VA
Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)
CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)
Status: Archived
Updated: 1/1/1970
VCU Medical Center
mi
from
Richmond, VA
Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)
CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)
Status: Archived
Swedish Medical Center
mi
from
Seattle, WA
Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)
CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)
Status: Archived
Updated: 1/1/1970
Swedish Medical Center
mi
from
Seattle, WA
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
A Randomized, Double-Blind, Placebo-Controlled Ascending Single-Dose Study of the Intravenous Infusion of CNTO 0007 in Subjects Who Have Experienced Ischemic Cerebral Infarction
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
A Randomized, Double-Blind, Placebo-Controlled Ascending Single-Dose Study of the Intravenous Infusion of CNTO 0007 in Subjects Who Have Experienced Ischemic Cerebral Infarction
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
A Randomized, Double-Blind, Placebo-Controlled Ascending Single-Dose Study of the Intravenous Infusion of CNTO 0007 in Subjects Who Have Experienced Ischemic Cerebral Infarction
Status: Archived
Clinical Trial Facility
mi
from
Detroit, MI
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
A Randomized, Double-Blind, Placebo-Controlled Ascending Single-Dose Study of the Intravenous Infusion of CNTO 0007 in Subjects Who Have Experienced Ischemic Cerebral Infarction
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Detroit, MI
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
A Randomized, Double-Blind, Placebo-Controlled Ascending Single-Dose Study of the Intravenous Infusion of CNTO 0007 in Subjects Who Have Experienced Ischemic Cerebral Infarction
Status: Archived
Clinical Trial Facility
mi
from
Medford, OR
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
A Randomized, Double-Blind, Placebo-Controlled Ascending Single-Dose Study of the Intravenous Infusion of CNTO 0007 in Subjects Who Have Experienced Ischemic Cerebral Infarction
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Medford, OR
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
A Randomized, Double-Blind, Placebo-Controlled Ascending Single-Dose Study of the Intravenous Infusion of CNTO 0007 in Subjects Who Have Experienced Ischemic Cerebral Infarction
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
A Randomized, Double-Blind, Placebo-Controlled Ascending Single-Dose Study of the Intravenous Infusion of CNTO 0007 in Subjects Who Have Experienced Ischemic Cerebral Infarction
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
A Randomized, Double-Blind, Placebo-Controlled Ascending Single-Dose Study of the Intravenous Infusion of CNTO 0007 in Subjects Who Have Experienced Ischemic Cerebral Infarction
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
A Randomized, Double-Blind, Placebo-Controlled Ascending Single-Dose Study of the Intravenous Infusion of CNTO 0007 in Subjects Who Have Experienced Ischemic Cerebral Infarction
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Glyburide Advantage in Malignant Edema and Stroke Pilot
A Two-center, Prospective, Open Label, Phase IIa Trial of RP-1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Experience Clinically Significant Brain Swelling.
Status: Archived
University of Maryland, Baltimore
mi
from
Baltimore, MD
Glyburide Advantage in Malignant Edema and Stroke Pilot
A Two-center, Prospective, Open Label, Phase IIa Trial of RP-1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Experience Clinically Significant Brain Swelling.
Status: Archived
Updated: 1/1/1970
University of Maryland, Baltimore
mi
from
Baltimore, MD
Glyburide Advantage in Malignant Edema and Stroke Pilot
A Two-center, Prospective, Open Label, Phase IIa Trial of RP-1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Experience Clinically Significant Brain Swelling.
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Glyburide Advantage in Malignant Edema and Stroke Pilot
A Two-center, Prospective, Open Label, Phase IIa Trial of RP-1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Experience Clinically Significant Brain Swelling.
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Optima Coronary Artery Disease (CAD) (Optimal Mechanical Evaluation)
Optima CAD (Optimal Mechanical Evaluation)
Status: Archived
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Optima Coronary Artery Disease (CAD) (Optimal Mechanical Evaluation)
Optima CAD (Optimal Mechanical Evaluation)
Status: Archived
Updated: 1/1/1970
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Intravascular Near Infrared Spectroscopy (NIRS) Bifurcation - Lipid Core Plaque Shift Study
Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Intravascular Near Infrared Spectroscopy (NIRS) Bifurcation - Lipid Core Plaque Shift Study
Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)
The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)
Status: Archived
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)
The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Using Duke Activity Status Index (DASI) to Select Optimal Cardiac Stress Tests
Clinical Role of the Duke Activity Status Index in the Selection of the Optimal Type of Stress Myocardial Perfusion Imaging Study in Patients With Known or Suspected Ischemic Heart Disease
Status: Archived
New York University Langone Medical Center
mi
from
New York, NY
Using Duke Activity Status Index (DASI) to Select Optimal Cardiac Stress Tests
Clinical Role of the Duke Activity Status Index in the Selection of the Optimal Type of Stress Myocardial Perfusion Imaging Study in Patients With Known or Suspected Ischemic Heart Disease
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
mi
from
New York, NY
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent
Status: Archived
Clinical Research Facility
mi
from
Miami, FL
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Miami, FL
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent
Status: Archived
Aurora Memorial Hospital of Burlington
mi
from
Burlington, WI
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent
Status: Archived
Updated: 1/1/1970
Aurora Memorial Hospital of Burlington
mi
from
Burlington, WI
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent
Status: Archived
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
mi
from
Scarborough, ME
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent
Status: Archived
Updated: 1/1/1970
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
mi
from
Scarborough, ME
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent
Status: Archived
Clinical Research Facility
mi
from
Brooklyn, NY
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Brooklyn, NY
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent
Status: Archived
Clinical Research Facility
mi
from
Portland, OR
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Portland, OR